nesvacumab

In its biopharma catalysts tracker released March 1, Leerink termed the year 2017 as a busy one for Neuro and Oncology. The firm highlighted the important catalysts for 2017. Celgene — Multiple Readout In 2017 On Celgene Corporation (NASDAQ: CELG), the firm noted that it has multiple readouts...

The ongoing Phase 2 studies of Regeneron Pharmaceuticals Inc’s (NASDAQ: REGN) nesvacumab could yield a favorable outcome, expanding the market opportunity for the company in wet Age-related Macular Degeneration [wet AMD] and Diabetic Macular Edema [DME], BTIG’s Dane Leone said in a...